Pegfilgrastim Biosimilars: Where Are We Now?
July 12, 2021
-
17 min
6 Key Takeaways
-
1
Neutropenia is defined as ANC < 500 cells/mm
-
2
Febrile neutropenia is a significant complication with serious risks.
-
3
G-CSFs like pegfilgrastim reduce infection risk during chemotherapy.
-
4
New biosimilars provide similar efficacy at potentially lower costs.
-
5
Bioequivalence testing is crucial for establishing safety and efficacy of biosimilars.
-
6
Recommended for chemotherapy regimens with high FN risk are G-CSFs.
Chemotherapy-induced neutropenia presents a significant challenge in cancer treatment, defined as an ANC < 500 cells/mm3 and associated febrile neutropenia (FN) risks. With serious infections and complications in about 30% of FN cases, timely prophylactic intervention is crucial. Granulocyte colony-stimulating factors (G-CSF) like pegfilgrastim are recommended to mitigate these risks. New biosimilars of pegfilgrastim offer similar efficacy and safety at potentially lower costs, expanding patient access and supporting optimal cancer treatment plans.
Listen Tab content
